Purification of monoclonal anti-B7-H4 antibody and the blockade of B7-H4-mediated tumor immune evasion by the antibody

CHEN Yali; LI Anqi; ZHANG Ningyue; ZHANG Liang

doi:10.11665/j.issn.1000-5048.20170411

Journal of China Pharmaceutical University > 2017 > 48(4): 461-468. > DOI: 10.11665/j.issn.1000-5048.20170411

CHEN Yali, LI Anqi, ZHANG Ningyue, ZHANG Liang. Purification of monoclonal anti-B7-H4 antibody and the blockade of B7-H4-mediated tumor immune evasion by the antibody[J]. Journal of China Pharmaceutical University, 2017, 48(4): 461-468. DOI: 10.11665/j.issn.1000-5048.20170411

Citation:

PDF (3424 KB)

Purification of monoclonal anti-B7-H4 antibody and the blockade of B7-H4-mediated tumor immune evasion by the antibody

More Information

Graphical Abstract

Abstract

Abstract

The purified 3C8 was obtained by two step column purification, including Protein G affinity purification and DEAE anion exchange purification. The purity of purified 3C8 was about 93% when analyzed by reverse column. SDS-PAGE showed that the purity of 3C8 was increased greatly by two step purification. By flowcytometry we found that 3C8 specifically binded with B7-H4/293T cells and did not bind with Mock/293T cells, moreover 3C8 did not bind with other B7 family members transgene cells. In confocal experiment 3C8 could specifically stained B7-H4/293T cells. In Western blot only B7-H4/293T cells showed positive band while Mock/293T cells showed negative result. The result of immunohistochemistry showed that B7-H4 was highly expressed in prostate cancer and renal cell carcinoma, while para-cancer tissues did not express B7-H4. The T cell proliferation experiment showed that B7-H4-Ig could bind to activate T cells and inhibit T cell proliferation, while 3C8 could block the binding of B7-H4-Ig and reverse the T cell proliferation inhibition effect of B7-H4-Ig by CFSE and CCK8 assay. The cytokine IFN-γ and IL-2 secreted by activating T cells was decreased by B7-H4-Ig and 3C8 could reverse the effect of B7-H4-Ig.
- monoclonal antibody 3C8,
- B7-H4,
- purification,
- negative costimulation,
- immune evasion,
- blockade

FullText(HTML)

References (15)

References

[1]	Bretscher PA.A two-step,two-signal model for the primary activation of precursor helper T cells[J].Proc Natl Acad Sci U S A,1999,96(1):185-190.
[2]	Schildberg FA,Klein SR,Freeman GJ,et al.Coinhibitory pathways in the B7-CD28 ligand-receptor family[J].Immunity,2016,44(5):955-972.
[3]	Swaika A,Hammond WA,Joseph RW.Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy[J].Mol Immunol,2015,67(2 Pt A):4-17.
[4]	Sica GL,Choi IH,Zhu G,et al.B7-H4,a molecule of the B7 family,negatively regulates T cell immunity[J].Immunity,2003,18(6):849-861.
[5]	Prasad DV,Richards S,Mai XM,et al.B7S1,a novel B7 family member that negatively regulates T cell activation[J].Immunity,2003,18(6):863-873.
[6]	Zang X,Loke P,Kim J,et al.B7x:a widely expressed B7 family member that inhibits T cell activation[J].Proc Natl Acad Sci U S A,2003,100(18):10388-10392.
[7]	Awadallah NS,Shroyer KR,Langer DA,et al.Detection of B7-H4 and p53 in pancreatic cancer:potential role as a cytological diagnostic adjunct[J].Pancreas,2008,36(2):200-206.
[8]	Miyatake T,Tringler B,Liu W,et al.B7-H4(DD-O110)is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration[J].Gynecol Oncol,2007,106(1):119-127.
[9]	Podojil JR,Miller SD.Potential targeting of B7-H4 for the treatment of cancer[J].Immunol Rev,2017,276(1):40-51.
[10]	Ni L,Dong C.New B7 family checkpoints in human cancers[J].Mol Cancer Ther,2017,16(7):1203-1211.
[11]	MacGregor HL,Ohashi PS.Molecular pathways:evaluating the potential for B7-H4 as an immunoregulatory target[J].Clin Cancer Res,2017,23(12):2934-2941.
[12]	Jeon H,Vigdorovich X,Garrett-Thomson SC,et al.Structure and cancer immunotherapy of the B7 family member B7x[J].Cell Rep,2014,9(3):1089-1098.
[13]	Dangaj D,Lanitis E,Zhao A,et al.Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses[J].Cancer Res,2013,73(15):4820-4829.
[14]	Dangaj D,Scholler N.Isolation and validation of Anti-B7-H4 scFvs from an ovarian cancer scFv yeast-display library[J].Methods Mol Biol,2015,1319:37-49.
[15]	Leong SR,Liang WC,Wu Y,et al.An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer[J].Mol Pharm,2015,12(6):1717-1729.

Cited By

Cited by

Periodical cited type(2)

1.	宋伏洋，韩东，黄壮壮，李波，彭修娟，许刚，杨青，赵扬，王苗，李叶，朱勇乐，刘峰. 基于UPLC-Q-TOF-MS/MS技术及肝纤维化细胞模型的肝爽颗粒抗肝纤维化的药效成分筛选研究. 中南药学. 2024(05): 1157-1163 .
2.	杨成，胡锴，韩鹏昭，宋军营，张振强，孙宁，王潘，谢治深，李中华. 天智颗粒的化学成分及入血成分定性分析. 中国药房. 2022(24): 2973-2977+2984 .

Other cited types(2)

Get Citation

PDF

XML

Article views PDF downloads Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

Purification of monoclonal anti-B7-H4 antibody and the blockade of B7-H4-mediated tumor immune evasion by the antibody

Abstract

References

Cited by

Periodical cited type(2)

Other cited types(2)

Catalog

Export File

Citation

Format

Content